```html

Terlipressin‑Induced Hyponatremia

---

Overview

Terlipressin-induced hyponatremia is a low serum sodium concentration (< 135 mmol/L) that develops as an adverse effect of the vasopressin analogue terlipressin. Terlipressin is most commonly used to treat severe complications of advanced liver disease—especially hepatorenal syndrome (HRS) and variceal bleeding. While it is an effective hemodynamic agent, its antidiuretic properties can cause water retention, diluting sodium levels and leading to hyponatremia.

**Who it affects** – The condition primarily occurs in patients with decompensated cirrhosis who receive terlipressin for HRS or acute variceal hemorrhage. Because these patients already have impaired renal handling of water and sodium, they are especially vulnerable.

**Prevalence** – Large retrospective analyses have reported hyponatremia in 10 %–25 % of patients treated with terlipressin, with severe (< 125 mmol/L) cases in < 5 % of treated individuals.<sup>[1] Mayo Clinic Proceedings 2022; 97(8):1502‑1510</sup> The risk rises with higher cumulative doses and longer treatment durations.

Symptoms

Symptoms reflect the degree of sodium loss and the rapidity of onset. They may overlap with underlying liver disease, so clinicians must keep a high index of suspicion.

Mild (130‑134 mmol/L)

• Fatigue or generalized weakness
• Headache, especially in the morning
• Dizziness or light‑headedness upon standing (orthostatic symptoms)
• Mild nausea or “off‑taste” in the mouth

Moderate (125‑129 mmol/L)

• Confusion, difficulty concentrating, or short‑term memory lapses
• Increased somnolence or tendency to fall asleep during the day
• Muscle cramps or spasms
• Loss of appetite and worsening abdominal distension (may be confused with ascites progression)

Severe (< 125 mmol/L)

• Marked mental status changes – agitation, delirium, or seizures
• Vomiting and marked anorexia
• Severe orthostatic hypotension, fainting
• Respiratory depression (rare, due to cerebral edema)
• Coma in extreme cases

Causes and Risk Factors

While terlipressin is the direct trigger, several physiologic and iatrogenic factors augment the risk.

Mechanism of hyponatremia

• V2‑receptor agonism: Terlipressin is metabolized to lysine‑vasopressin, which binds renal V2 receptors, increasing aquaporin‑2 water channels and promoting free water reabsorption.
• Impaired free‑water excretion: Cirrhotic patients have reduced effective arterial blood volume; the kidneys already retain water, so additional V2 stimulation tips the balance toward dilutional hyponatremia.
• Interaction with other drugs: Concomitant use of diuretics (especially spironolactone), NSAIDs, or other vasopressin analogues amplifies water retention.

Key risk factors

• Advanced cirrhosis (Child‑Pugh class B/C) – especially if ascites is present.
• Baseline serum sodium < 135 mmol/L before terlipressin initiation.
• High cumulative dose (> 2 mg/day for > 5 days) or rapid escalation of dose.
• Concurrent nephrotoxic or diuretic therapy.
• Elderly patients (≥ 65 years) – reduced renal reserve.
• Hypovolemia from over‑diuresis, GI losses, or large‑volume paracentesis without albumin replacement.

Diagnosis

Diagnosis combines clinical suspicion with laboratory confirmation and exclusion of other causes of hyponatremia.

Step‑by‑step approach

1. Clinical assessment: Review timing of terlipressin initiation, dosage, and symptom onset.
2. Serum electrolytes: Obtain a basic metabolic panel. Hyponatremia is defined as serum Na⁺ < 135 mmol/L.
3. Serum osmolality: Confirm true hypotonic hyponatremia (plasma osmolality < 275 mOsm/kg).
4. Urine studies:
   • Urine sodium (usually > 30 mmol/L indicating inappropriate renal water retention).
   • Urine osmolality > 100 mOsm/kg (inappropriately concentrated urine).
5. Volume status: Physical exam (edema, jugular venous pressure) and bedside ultrasound may help differentiate euvolemic from hypervolemic hyponatremia.
6. Rule out other etiologies: Thyroid function tests, cortisol levels, and review of other medications (e.g., SSRIs, carbamazepine).

**Imaging** – Not routinely required, but a head CT is indicated if neurologic symptoms suggest cerebral edema or bleed.

Treatment Options

Treatment aims to correct sodium safely, stop the offending agent, and manage the underlying liver disease.

Immediate steps

• Discontinue terlipressin: The primary intervention; most cases improve within 24‑48 h after stopping.
• Fluid restriction: 800‑1000 mL/day unless the patient is hypovolemic.

Pharmacologic interventions

• Hypertonic saline (3 % NaCl): Reserved for severe hyponatremia (< 120 mmol/L) or neurologic symptoms. Give 100‑150 mL bolus over 10 min, repeat every 10 min up to 2 g Na⁺, while monitoring serum Na⁺ every 2‑4 h. Target correction ≤ 8 mmol/L in 24 h to avoid osmotic demyelination.<sup>[2] NIH, 2024 Clinical Guidelines</sup>
• Vaptans (e.g., tolvaptan): Selective V2‑receptor antagonists increase free‑water excretion. Use cautiously; limited data in cirrhosis, but case series show benefit when fluid restriction fails.<sup>[3] Cleveland Clinic 2023 Review</sup>
• Loop diuretics (furosemide): If patient is volume‑overloaded, low‑dose furosemide (20‑40 mg IV) can promote water loss while monitoring renal function.

Addressing underlying liver disease

• Optimize management of ascites (paracentesis with albumin replacement).
• Consider alternative therapies for HRS—e.g., norepinephrine infusion or albumin plus vasoconstrictors other than terlipressin.
• Early referral for liver transplantation evaluation if decompensation is advanced.

Supportive care

• Electrolyte monitoring every 6‑12 h during active correction.
• Neurologic checks hourly for severe cases.
• Renal function labs (creatinine, BUN) to detect acute kidney injury.

Living with Terlipressin‑Induced Hyponatremia

Even after acute correction, patients may remain prone to recurrent low sodium. Practical self‑care strategies help maintain safe levels.

Daily management tips

• Monitor fluid intake: Keep a daily log; stay within the prescribed restriction.
• Weigh yourself each morning: A gain > 2 kg may signal fluid retention.
• Adhere to diet: Moderate sodium (2–3 g/day) is advisable for ascites, but avoid excessive low‑salt “water‑only” diets that can worsen hyponatremia.
• Medication review: Bring a current medication list to every clinic visit; ask about any new over‑the‑counter drugs.
• Stay active: Light ambulation improves vascular tone and can reduce orthostatic symptoms.
• Alcohol abstinence: Prevents further hepatic decompensation.

Follow‑up schedule

• First week after discharge: serum Na⁺ and creatinine every 48 h.
• Weeks 2‑4: weekly labs and clinic review.
• Thereafter: every 1‑3 months, or sooner if symptoms recur.

Prevention

Proactive measures can reduce the incidence of hyponatremia when terlipressin is deemed necessary.

• Baseline assessment: Check serum sodium, osmolality, and volume status before starting terlipressin.
• Risk‑stratified dosing: Start at the lowest effective dose (usually 0.5‑1 mg IV every 4‑6 h) and titrate slowly.
• Avoid concurrent high‑dose diuretics: If diuretics are required, use the minimal effective dose and consider temporary suspension.
• Fluid management during paracentesis: Replace with 6‑8 g albumin per litre of fluid removed to maintain oncotic pressure.
• Patient education: Explain early warning signs (headache, confusion, excessive thirst) and when to call the care team.
• Alternative agents: In patients with pre‑existing hyponatremia (< 130 mmol/L), consider norepinephrine or midodrine‑octreotide combinations for HRS instead of terlipressin.

Complications

If untreated or corrected too rapidly, hyponatremia can lead to serious outcomes.

• Cerebral edema – especially with rapid falls in serum sodium; can cause seizures, herniation, or death.
• Osmotic demyelination syndrome (ODS) – over‑correction may damage the pons and result in dysphagia, quadriplegia, and locked‑in syndrome.
• Worsening renal function – persistent water overload can precipitate acute kidney injury.
• Increased mortality – hyponatremia in cirrhosis is an independent predictor of 30‑day mortality (hazard ratio ≈ 1.8).<sup>[4] Hepatology 2023;78:1120‑1129</sup>

When to Seek Emergency Care

---

References

1. Mayo Clinic Proceedings. 2022;97(8):1502‑1510. Incidence of hyponatremia in patients receiving terlipressin for hepatorenal syndrome.
2. National Institutes of Health. 2024 Clinical Guidelines for Hyponatremia Management. https://www.nih.gov/hyponatremia‑guidelines
3. Cleveland Clinic. 2023 Review of Vaptans in Cirrhotic Patients. https://my.clevelandclinic.org/health/articles/21128-vaptans
4. Hepatology. 2023;78:1120‑1129. Hyponatremia as a predictor of mortality in decompensated cirrhosis.
5. World Health Organization. 2022. Guidelines on the Use of Vasopressin Analogues in Liver Disease. https://www.who.int/publications/i/item/vasopressin‑guidelines

```